Financials
Financial year 2025
Phoenix Biosciences from Nivelles, company number BE1027640071, closed financial year 2025 with a result of € -2.8 million after tax. For that financial year Phoenix Biosciences recorded revenue of € 1.3 million and equity of € 3.7 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 26, 2026.
€ 3.7 million
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -2.8 million
Profit after tax over the fiscal year.
€ 4.7 million
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -2.8 million.
People and assets in 2025
8.3
Average over the fiscal year, from the social balance sheet.
€ 956,882
€ 115,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 39,193
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 3 million
Loans from banks and other lenders, long and short.
€ 498,142
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 165 days on average.
€ 385,107
Taxes, VAT and social contributions still to pay.
What happened to Phoenix Biosciences?
What happened at Phoenix Biosciences in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Frank MESTDAGH stepped down as director. NBB
- José CASTILLO FERNANDEZ stepped down as director. NBB
- GFB CONSULT stepped down as director. NBB
- KHAN Mohammed stepped down as director. NBB
- ROCKMAN Glenn stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 2.8 million. Source: NBB ↗
- GFB CONSULT became a director. NBB
- KHAN Mohammed became a director. NBB
In short
Pays suppliers within 165 days on average.
Management
Directors
According to the 2025 annual accounts
ROCKMAN Glenn
Director
since 2025 · until 2031
Director
Also active at: CTC GROUP, TheClubDeal Capital Advisors, YUST Group, THECLUBDEAL FUND II
since 2025 · until 2031
since 2025 · until 2032
KHAN Mohammed
Director
since 2025 · until 2031
since 2025 · until 2032
Establishments
Establishment units
Physical locations of this company
rue de la Maitrise 11
1400 Nivelles
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
VERIXI, BE
Domain
Domain
quantoom.com
Registered
2019-10-25
Registrar
Combell NV
Expires
2027-10-25
Website info
Features
Security
Details
- Company number
- 1027.640.071
- VAT number
- BE 1027.640.071
- Registered office
- rue de la Maitrise 11, 1400 Nivelles
- Names & denominations
- Phoenix Biosciences
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 15 September 2025
- Peppol
- Active · Active since 17 Nov 2025
- Contact
- quantoom.com
- Activities · NACE
Vervaardiging van overige farmaceutische producten
Speur- en ontwikkelingswerk op biotechnologisch gebied
Vervaardiging van meet-, controle- en navigatie-instrumenten en -apparatuur